Nanoform 1-12/2020 report and new company near-term target introduced Nanoform Company Announcement Nanoform 1-12/2020 report and new company near-term target introduced First GMP manufacturing campaign and first dosing in humans successfully completed, positive interim results from first clinical study announced, all near-term business targets set out in IPO achieved, ten new Small Molecule PoC projects started, four more non-GMP lines commissioned, first Biologics PoC project commenced and a new near-term business target introduced: “At least 3 new non-GMP lines in 2021 and 2 new GMP lines in 2022”. 10-12/2020 key financials: - Revenue was EUR 186 thousand (EUR 49 thousand in 10-12/2019). - The gross profit and margin came in at EUR 135 thousand and 73%, during 10-12/2019 the gross profit was negative.